Akero Therapeutics (AKRO) Competitors $45.79 -0.31 (-0.67%) As of 02:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKRO vs. RDY, ASND, VTRS, ROIV, QGEN, ELAN, BBIO, MRNA, VRNA, and RVMDShould you be buying Akero Therapeutics stock or one of its competitors? The main competitors of Akero Therapeutics include Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), Roivant Sciences (ROIV), QIAGEN (QGEN), Elanco Animal Health (ELAN), BridgeBio Pharma (BBIO), Moderna (MRNA), Verona Pharma PLC American Depositary Share (VRNA), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry. Akero Therapeutics vs. Its Competitors Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris Roivant Sciences QIAGEN Elanco Animal Health BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Revolution Medicines Dr. Reddy's Laboratories (NYSE:RDY) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation. Do institutionals and insiders hold more shares of RDY or AKRO? 3.8% of Dr. Reddy's Laboratories shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 7.1% of Akero Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend RDY or AKRO? Dr. Reddy's Laboratories currently has a consensus target price of $16.95, suggesting a potential upside of 19.83%. Akero Therapeutics has a consensus target price of $81.14, suggesting a potential upside of 77.09%. Given Akero Therapeutics' higher possible upside, analysts plainly believe Akero Therapeutics is more favorable than Dr. Reddy's Laboratories.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Akero Therapeutics 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.78 Which has stronger earnings & valuation, RDY or AKRO? Dr. Reddy's Laboratories has higher revenue and earnings than Akero Therapeutics. Akero Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDr. Reddy's Laboratories$334.26B0.04$663M$0.6621.43Akero TherapeuticsN/AN/A-$252.06M-$2.00-22.91 Is RDY or AKRO more profitable? Dr. Reddy's Laboratories has a net margin of 16.99% compared to Akero Therapeutics' net margin of 0.00%. Dr. Reddy's Laboratories' return on equity of 17.25% beat Akero Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dr. Reddy's Laboratories16.99% 17.25% 11.63% Akero Therapeutics N/A -15.84%-14.59% Does the media prefer RDY or AKRO? In the previous week, Akero Therapeutics had 4 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Akero Therapeutics and 1 mentions for Dr. Reddy's Laboratories. Dr. Reddy's Laboratories' average media sentiment score of 1.86 beat Akero Therapeutics' score of 0.55 indicating that Dr. Reddy's Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Akero Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, RDY or AKRO? Dr. Reddy's Laboratories has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.29, suggesting that its stock price is 129% less volatile than the S&P 500. SummaryDr. Reddy's Laboratories beats Akero Therapeutics on 12 of the 16 factors compared between the two stocks. Get Akero Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKRO vs. The Competition Export to ExcelMetricAkero TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.67B$3.34B$6.11B$10.62BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-22.9122.1285.7127.13Price / SalesN/A265.70527.78206.21Price / CashN/A46.3226.3031.12Price / Book4.269.9612.886.68Net Income-$252.06M-$52.35M$3.30B$275.95M7 Day Performance-3.78%5.89%4.28%3.24%1 Month Performance2.46%11.54%7.57%10.67%1 Year Performance62.25%24.98%75.50%33.82% Akero Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKROAkero Therapeutics3.7382 of 5 stars$45.82-0.6%$81.14+77.1%+63.2%$3.67BN/A-22.9130Positive NewsAnalyst UpgradeInsider TradeRDYDr. Reddy's Laboratories3.2826 of 5 stars$13.96-1.9%$16.95+21.5%-9.5%$11.87B$334.26B21.1427,811Positive NewsASNDAscendis Pharma A/S2.9956 of 5 stars$191.60-0.2%$244.36+27.5%+43.0%$11.83B$393.54M-37.131,017VTRSViatris1.1631 of 5 stars$9.62+1.1%$10.40+8.1%-12.1%$11.10B$14.74B-3.3232,000ROIVRoivant Sciences3.4279 of 5 stars$15.10-0.5%$19.94+32.0%+42.1%$10.36B$23.23M-21.57860QGENQIAGEN4.4621 of 5 stars$43.880.0%$49.69+13.2%+10.5%$9.76B$1.98B25.935,765Analyst DowngradeELANElanco Animal Health2.5065 of 5 stars$19.63+0.1%$18.33-6.6%+40.8%$9.74B$4.44B22.829,000BBIOBridgeBio Pharma4.1948 of 5 stars$51.96+3.8%$63.94+23.1%+109.5%$9.57B$221.90M-12.70400MRNAModerna4.3419 of 5 stars$25.33+3.4%$41.81+65.1%-52.7%$9.53B$3.24B-3.365,800VRNAVerona Pharma PLC American Depositary Share1.9284 of 5 stars$106.61-0.1%$109.00+2.2%+233.6%$9.20B$42.28M-107.6930Positive NewsRVMDRevolution Medicines4.2981 of 5 stars$46.07+4.9%$74.64+62.0%-1.3%$8.21B$11.58M-10.24250 Related Companies and Tools Related Companies Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives Roivant Sciences Alternatives QIAGEN Alternatives Elanco Animal Health Alternatives BridgeBio Pharma Alternatives Moderna Alternatives Verona Pharma PLC American Depositary Share Alternatives Revolution Medicines Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKRO) was last updated on 10/6/2025 by MarketBeat.com Staff From Our PartnersWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the ...Banyan Hill Publishing | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akero Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akero Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
